Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DDO | Q99489 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207651 | 0.76 | AHR (0.43) | CYP1A2NOS3NOS1NOS2NR4A2 | |
| SCHEMBL207535 | 0.74 | AHR (0.42) | CYP2A6NOS1HTR2ANR4A2ALDH1A1 | |
| SCHEMBL1968319 | 0.74 | MEN1 (0.47) | CA12CA9CYP1A2RXFP1HTR2A | |
| SCHEMBL6345184 | 0.70 | HPGD (0.47) | KMT2APOLBUSP2ALDH1A1HPGD | |
| SCHEMBL6954043 | 0.69 | HSD17B10 (0.42) | KIF11CA12CA9CYP1A2KMT2A | |
| SCHEMBL17423817 | 0.69 | — | — | |
| SCHEMBL6015959 | 0.69 | MEN1 (0.32) | KMT2APOLB | |
| SCHEMBL25289152 | 0.68 | KDM4E (0.45) | KIF11CA12CA9HTR2ANR4A2 | |
| SCHEMBL4502393 | 0.68 | KDM4E (0.49) | CA12CA9KMT2APOLBALDH1A1 | |
| SCHEMBL9537298 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| CN-111533767-A | Tetradentate phosphine ligand and preparation method thereof, hydroformylation catalyst and reaction method, and preparation method of 1, 3-propylene glycol | 卢海元 | 2020-08-14 | — | — | CN | claimed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | claimed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | claimed |
| US-6333339-B1 | CENTRAL SYSTEM DISORDERS, SCHIZOPHRENIA AND COGNITION ACTIVATORS | MERCK PATENT GELLSCHAFT MIT BESCHRANKTER (DE) | 2001-12-25 | — | — | US | claimed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | claimed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | claimed |
| US-4870087-A | Indole containing, 2-thienyl-1,2,3,6-tetrahydropyridyls and their pharmaceutical use | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-09-26 | — | — | US | claimed |
| US-4617309-A | Sulfur-containing indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-115181053-A | Preparation method of chiral tetraaryl substituted methane | 香港科技大学深圳研究院 | 2022-10-14 | — | — | CN | disclosed |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-4617309-A | Sulfur-containing indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0105397-B1 | SULPHURIC INDOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0121716-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-10-17 | — | — | EP | disclosed |
| EP-0114603-A1 | Indole derivatives | MERCK PATENT GmbH (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0105397-A1 | Sulphuric indole derivatives | MERCK PATENT GmbH (DE) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | KIF11 2376/4885CA12 2407/4885CA9 1199/4885 |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | KIF11 3015/4885CA12 4421/4885CA9 4545/4885 |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | KIF11 3953/4885CA12 4713/4885CA9 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.